Burden of BMI on Costs of Musculoskeletal Diseases A cross-sectional global study shows a substantial impact of obesity and BMI on the health and economic impact of patients with musculoskeletal (MSK) disorders. https://t.co/EZJTnLeaOZ https://t.co/sAOQ3fuq8Z

Subanalysis of Scleroderma Lung Study II (MMP vs CTX in SSc-ILD) showed pt reported GI reflux (~moderate) was independently associated with the change ILD and fibrosis over two years (but not so for esophageal dilation) https://t.co/6wRCM0PW2a https://t.co/uc2dfdnlhu

Free read review of IL-15 - crucial for the homeostasis of NK & memory CD8 T cells; IL-15 dysregulations are important autoimmune Dz & hematological malignancies. How to target the actions of IL-15 are discussed https://t.co/yUuUIOCAC6 https://t.co/nLnC37GdMS

FDA oversees US drug sales, the largest single market for pharmaceuticals globally, worth an estimated $528 billion in 2020 in public and private spending (Figure 1). https://t.co/DMwoYIIyHP https://t.co/9nGStaotrO

Inpatient health care utilization studied in 341 #SLE pts vs 341 non-SLE. SLE had more hospitalizations (30 vs 10/100PY) and more ED visit (HR 2.71) and Hospital readmission rates (32% vs. 21%, p = 0.017) https://t.co/vsW7Ol9b4O https://t.co/hpmcFuF8Pm

Korean study of 439 RA pts starting JAKi, TNFi or non-TNFi. Physician choice of JAKi was more likely with age (OR 1.03), no pulmonary Dz (OR 0.07), Higher Dz activity (OR 1.80) & prior tacrolimus (OR 2.05) https://t.co/9Vv5XfzfrH https://t.co/59Whi7tCIE

JAMA: 13 million In US have latent TB (5-10% risk of getting active TB). Review of LTBI regimens: - Preferred: 4 mos Rifampin: better/safer of INH - Preferred: 3 mos of INH + rifapentine - more completers less SAE - ALternative: 6-9 mos of INH https://t.co/vZTmSKTFWu https://t.co/W7BraJs6yC

PsA Til Death Do Us Part Dr. Jack Cush reviews the highlights from the past week on RheumNow https://t.co/nSogWCSbi9 https://t.co/nZ9jWu20Xy

AS, but not PsA, has Increased Mortality Risk A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA), largely associated with cardiovascular-specific mortality. https://t.co/gnd0bMQIui https://t.co/sWFhJAIaGH

Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. https://t.co/pdfxa3u29k https://t.co/0wLl48Fvj6

PRedSS was a small trial of 35 pts with early diffuss systemic sclerosis Rx w/ prednisolone(17) vs placebo(18). At 3 mos outcomes favored Pred, but nonsignificant (HAQ-DI -0.10; p= 0.25 & mRSS -3.90; p= 0.07), but less pain & anxiety https://t.co/iZw2L9SLhF https://t.co/2G2MuVMUSJ

Danish registries stud of > 6 million persons finds 52898 new #IBD pts (over 18 yrs). Antibiotic exposure was assoc w/ increased risk of IBD, esp > 40 yrs. (40–60 yrs IRR 1.48; ≥60 yrs IRR 1.47) https://t.co/qU1OxXr7Gj https://t.co/YMh6L514By